Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), filed a Form 4 on September 11, 2026, disclosing the exercise of stock options and the sale of 10,185 shares of common stock on September 10, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Sullivan acquired 10,185 shares of common stock via stock option exercise (transaction code M) at an exercise price of $8.04 per share on September 10, 2026.
  • Shares sold: Sullivan disposed of 10,185 shares (transaction code S) at a weighted average price of $17.6197, with individual sale prices ranging from $17.17 to $17.95.
  • 10b5-1 plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Sullivan on May 18, 2026.
  • Remaining direct ownership: Following the transactions, Sullivan directly beneficially owns 39,900 shares of common stock.
  • Options remaining: Sullivan retains 105,815 stock options with an exercise price of $8.04 and an expiration date of January 28, 2035.

Sullivan's Option Exercise and Share Sale at Avalo Therapeutics

According to the filing, Christopher Ryan Sullivan, serving as Chief Financial Officer of Avalo Therapeutics, Inc., exercised stock options covering 10,185 shares of common stock on September 10, 2026, at an exercise price of $8.04 per share. On the same date, he sold those 10,185 shares at a reported average price of $17.6197. The filing notes that the sales were executed in multiple transactions at prices ranging from $17.17 to $17.95, and Sullivan has undertaken to provide full detail on shares sold at each separate price upon request.

The filing discloses that both the exercise and the sale were carried out under a Rule 10b5-1 trading plan that Sullivan adopted on May 18, 2026. Following these transactions, Sullivan directly holds 39,900 shares of Avalo Therapeutics common stock, compared to 50,085 shares beneficially owned immediately after the option exercise and before the sale, as reported in Table I of the filing.

In Table II, the filing shows that the underlying stock option carries an exercise price of $8.04 and expires on January 28, 2035. The option vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years, subject to Sullivan's continued service on each vesting date. After the reported exercise, Sullivan retains 105,815 stock options, held directly.

What Was Disclosed

The filing reports a same-day option exercise and share sale by Avalo Therapeutics' CFO on September 10, 2026, both conducted under a pre-established 10b5-1 plan, resulting in direct ownership of 39,900 shares and 105,815 remaining stock options.